Please login to the form below

Not currently logged in
Email:
Password:

SHP625

This page shows the latest SHP625 news and features for those working in and with pharma, biotech and healthcare.

Silver lining as Shire rare disease programme hits a setback

Silver lining as Shire rare disease programme hits a setback

Shire's SHP625 (formerly known as LUM001) - a bile acid transporter inhibitor designed to correct the liver defect in ALGS - missed all its objectives in the IMAGO study involving 20 children ... SHP625 was associated with a drop of 66.1 micromoles/L in

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics